Literature DB >> 9495567

Fetal antigen 1 (FA1), a circulating member of the epidermal growth factor (EGF) superfamily: ELISA development, physiology and metabolism in relation to renal function.

C H Jensen1, T N Krogh, R K Støving, U Holmskov, B Teisner.   

Abstract

We describe an ELISA technique for quantification of fetal antigen 1 (FA1), a glycoprotein belonging to the EGF-superfamily. The ELISA is based on immunospecifically purified polyclonal antibodies and has a dynamic range of 0.7-5.3 ng/ml, intra- and inter-assay C.V.s of less than 3.2% and an average recovery of 105% in serum and 98% in urine. Comparison of FA1 in amniotic fluid, serum and urine revealed parallel titration curves, identical elution volumes following size chromatography, immunological identity and similar profiles when analysed by MALDI-MS. The reference interval for serum FA1 was 12.3-46.6 ng/ml and the levels were 10 times higher in patients with renal failure. FA1 showed no diurnal variation, no variation during the menstrual cycle and was not influenced by the acute phase reaction. In humans (n = 10) the renal clearance of FA1 was 11 ml/min and an identical high renal clearance was found in rats when expressed per 100 g body weight. In rats the initial increase in serum FA1 was 10 ng/ml/h following bilateral nephrectomy, explaining the increased serum concentrations of FA1 observed in patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9495567     DOI: 10.1016/s0009-8981(97)00152-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Delta-like 1/fetal antigen-1 (Dlk1/FA1) is a novel regulator of chondrogenic cell differentiation via inhibition of the Akt kinase-dependent pathway.

Authors:  Li Chen; Diyako Qanie; Abbas Jafari; Hanna Taipaleenmaki; Charlotte H Jensen; Anna-Marja Säämänen; Maria Luisa Nueda Sanz; Jorge Laborda; Basem M Abdallah; Moustapha Kassem
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

2.  Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation.

Authors:  Yuhui Wang; Hei Sook Sul
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover.

Authors:  Basem M Abdallah; Anne-Christine Bay-Jensen; Bhuma Srinivasan; Nadine C Tabassi; Patrick Garnero; Jean-Marie Delaissé; Sundeep Khosla; Moustapha Kassem
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

4.  Isolation and differentiation of chondrocytic cells derived from human embryonic stem cells using dlk1/FA1 as a novel surface marker.

Authors:  Linda Harkness; Hanna Taipaleenmaki; Amer Mahmood; Ulrik Frandsen; Anna-Marja Saamanen; Moustapha Kassem; Basem M Abdallah
Journal:  Stem Cell Rev Rep       Date:  2009-12       Impact factor: 5.739

5.  Changes in satellite cells in human skeletal muscle after a single bout of high intensity exercise.

Authors:  Regina M Crameri; Henning Langberg; Peter Magnusson; Charlotte H Jensen; Henrik Daa Schrøder; Jens L Olesen; Charlotte Suetta; Børge Teisner; Michael Kjaer
Journal:  J Physiol       Date:  2004-04-30       Impact factor: 5.182

Review 6.  The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis.

Authors:  Michaela Tencerova; Moustapha Kassem
Journal:  Front Endocrinol (Lausanne)       Date:  2016-09-21       Impact factor: 5.555

7.  Serum levels of fetal antigen 1 in extreme nutritional States.

Authors:  Alin Andries; Andreas Niemeier; Rene K Støving; Basem M Abdallah; Anna-Maria Wolf; Kirsten Hørder; Moustapha Kassem
Journal:  ISRN Endocrinol       Date:  2012-07-15

8.  FA1 Induces Pro-Inflammatory and Anti-Adipogenic Pathways/Markers in Human Myotubes Established from Lean, Obese, and Type 2 Diabetic Subjects but Not Insulin Resistance.

Authors:  Basem M Abdallah; Henning Beck-Nielsen; Michael Gaster
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-05       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.